The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)



Gene Review

FXYD5  -  FXYD domain containing ion transport...

Homo sapiens

Synonyms: DYSAD, Dysadherin, FXYD domain-containing ion transport regulator 5, HSPC113, IWU1, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of FXYD5


High impact information on FXYD5


Chemical compound and disease context of FXYD5


Biological context of FXYD5


Anatomical context of FXYD5


Associations of FXYD5 with chemical compounds

  • Dysadherin is a cancer-associated cell membrane glycoprotein [4].
  • To assess the importance of O-glycosylation in dysadherin function, dysadherin-transfected hepatocarcinoma cells were cultured in a medium containing benzyl-alpha-GalNAc, a modulator of O-glycosylation [13].
  • We have compared the outcome of patients treated with conventional myeloablative regimens and CD34(+)-selected cells (CD34(+) group; n=23) with those receiving reduced-intensity conditioning regimens, consisting of fludarabine (150 mg/m(2)) plus an alkylating agent, followed by unmanipulated grafts (RIC group; n=27) [14].
  • Bone marrow plasma cells from RIC contained short gamma 1 heavy-chain transcripts in which a VDJ exon related to the VH2 subgroup was directly joined to the hinge exon; plasma cells from THR contained short gamma 1 transcripts with a VDJ exon related to the VH3 subgroup joined to the CH3 exon [15].
  • From our aroma extract dilu-tion analyses (AEDA) applied to naturally aged lager beers emerged an old-beer-like odorant at RICP-SIL 5 CB = 1532 and RIFFAP = 2809, with a FD value close to that of trans-2-nonenal (the well-known cardboard off-flavor found in aged beers) [16].

Regulatory relationships of FXYD5


Other interactions of FXYD5


Analytical, diagnostic and therapeutic context of FXYD5


  1. Dysadherin, a cancer-associated cell membrane glycoprotein, down-regulates E-cadherin and promotes metastasis. Ino, Y., Gotoh, M., Sakamoto, M., Tsukagoshi, K., Hirohashi, S. Proc. Natl. Acad. Sci. U.S.A. (2002) [Pubmed]
  2. Dysadherin overexpression in pancreatic ductal adenocarcinoma reflects tumor aggressiveness: relationship to e-cadherin expression. Shimamura, T., Sakamoto, M., Ino, Y., Sato, Y., Shimada, K., Kosuge, T., Sekihara, H., Hirohashi, S. J. Clin. Oncol. (2003) [Pubmed]
  3. Clinical significance of dysadherin expression in gastric cancer patients. Shimada, Y., Yamasaki, S., Hashimoto, Y., Ito, T., Kawamura, J., Soma, T., Ino, Y., Nakanishi, Y., Sakamoto, M., Hirohashi, S., Imamura, M. Clin. Cancer Res. (2004) [Pubmed]
  4. Dysadherin: expression and clinical significance in thyroid carcinoma. Sato, H., Ino, Y., Miura, A., Abe, Y., Sakai, H., Ito, K., Hirohashi, S. J. Clin. Endocrinol. Metab. (2003) [Pubmed]
  5. Chemokine (C-C motif) ligand 2 mediates the prometastatic effect of dysadherin in human breast cancer cells. Nam, J.S., Kang, M.J., Suchar, A.M., Shimamura, T., Kohn, E.A., Michalowska, A.M., Jordan, V.C., Hirohashi, S., Wakefield, L.M. Cancer Res. (2006) [Pubmed]
  6. High-dose chemotherapy using BEAM for tumor debulking without stem cell support followed by early allogeneic reduced intensity conditioning transplantation to induce a graft-versus-lymphoma effect in patients with high risk or refractory lymphoma. Buser, A.S., Heim, D., Bucher, C., Tichelli, A., Gratwohl, A., Passweg, J.R. Bone Marrow Transplant. (2004) [Pubmed]
  7. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol. Alvarez, I., Sureda, A., Caballero, M.D., Urbano-Ispizua, A., Ribera, J.M., Canales, M., García-Conde, J., Sanz, G., Arranz, R., Bernal, M.T., de la Serna, J., Díez, J.L., Moraleda, J.M., Rubió-Félix, D., Xicoy, B., Martínez, C., Mateos, M.V., Sierra, J. Biol. Blood Marrow Transplant. (2006) [Pubmed]
  8. Two-dimensional electrophoretic mobility shift assay: identification and mapping of transcription factor CTCF target sequences within an FXYD5-COX7A1 region of human chromosome 19. Vetchinova, A.S., Akopov, S.B., Chernov, I.P., Nikolaev, L.G., Sverdlov, E.D. Anal. Biochem. (2006) [Pubmed]
  9. Identification, genome mapping, and CTCF binding of potential insulators within the FXYD5-COX7A1 locus of human Chromosome 19q13.12. Akopov, S.B., Ruda, V.M., Batrak, V.V., Vetchinova, A.S., Chernov, I.P., Nikolaev, L.G., Bode, J., Sverdlov, E.D. Mamm. Genome (2006) [Pubmed]
  10. Involvement of dysadherin and E-cadherin in the development of testicular tumours. Batistatou, A., Scopa, C.D., Ravazoula, P., Nakanishi, Y., Peschos, D., Agnantis, N.J., Hirohashi, S., Charalabopoulos, K.A. Br. J. Cancer (2005) [Pubmed]
  11. Identification and mapping of DNA binding proteins target sequences in long genomic regions by two-dimensional EMSA. Chernov, I.P., Akopov, S.B., Nikolaev, L.G., Sverdlov, E.D. BioTechniques (2006) [Pubmed]
  12. Dysadherin expression facilitates cell motility and metastatic potential of human pancreatic cancer cells. Shimamura, T., Yasuda, J., Ino, Y., Gotoh, M., Tsuchiya, A., Nakajima, A., Sakamoto, M., Kanai, Y., Hirohashi, S. Cancer Res. (2004) [Pubmed]
  13. Aberrant O-glycosylation inhibits stable expression of dysadherin, a carcinoma-associated antigen, and facilitates cell-cell adhesion. Tsuiji, H., Takasaki, S., Sakamoto, M., Irimura, T., Hirohashi, S. Glycobiology (2003) [Pubmed]
  14. Strategies to reduce transplant-related mortality after allogeneic stem cell transplantation in elderly patients: Comparison of reduced-intensity conditioning and unmanipulated peripheral blood stem cells vs a myeloablative regimen and CD34+ cell selection. Canals, C., Martino, R., Sureda, A., Altés, A., Briones, J., Subirá, M., Ancín, I., Martín-Henao, G., Brunet, S., Sierra, J. Exp. Hematol. (2003) [Pubmed]
  15. Structure of abnormal heavy chains in human heavy-chain-deposition disease. Khamlichi, A.A., Aucouturier, P., Preud'homme, J.L., Cogné, M. Eur. J. Biochem. (1995) [Pubmed]
  16. Identification of a stale-beer-like odorant in extracts of naturally aged beer. Callemien, D., Dasnoy, S., Collin, S. J. Agric. Food Chem. (2006) [Pubmed]
  17. Prognostic significance of dysadherin expression in epithelioid sarcoma and its diagnostic utility in distinguishing epithelioid sarcoma from malignant rhabdoid tumor. Izumi, T., Oda, Y., Hasegawa, T., Nakanishi, Y., Iwasaki, H., Sonobe, H., Goto, H., Kusakabe, H., Takahira, T., Kobayashi, C., Kawaguchi, K., Saito, T., Yamamoto, H., Tamiya, S., Iwamoto, Y., Tsuneyoshi, M. Mod. Pathol. (2006) [Pubmed]
  18. Reduced-intensity conditioning regimen preserves thymic function in the early period after hematopoietic stem cell transplantation. Jiménez, M., Martínez, C., Ercilla, G., Carreras, E., Urbano-Ispízua, A., Aymerich, M., Villamor, N., Amézaga, N., Rovira, M., Fernández-Avilés, F., Gaya, A., Martino, R., Sierra, J., Montserrat, E. Exp. Hematol. (2005) [Pubmed]
  19. Increased incidence of EBV-related disease following paediatric stem cell transplantation with reduced-intensity conditioning. Cohen, J., Gandhi, M., Naik, P., Cubitt, D., Rao, K., Thaker, U., Davies, E.G., Gaspar, H.B., Amrolia, P.J., Veys, P. Br. J. Haematol. (2005) [Pubmed]
  20. Health-related quality of life in patients receiving reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation. Bevans, M.F., Marden, S., Leidy, N.K., Soeken, K., Cusack, G., Rivera, P., Mayberry, H., Bishop, M.R., Childs, R., Barrett, A.J. Bone Marrow Transplant. (2006) [Pubmed]
WikiGenes - Universities